A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T‐Cell Lymphoma
- DOI
- 10.1002/hon.70235
- Published
- 2026-08-03
- Container
- Hematological Oncology
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/hon.70235,
title = {A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T‐Cell Lymphoma},
author = {Hayder Saeed and Melanie Mediavilla Varela and Eva Sahakian and Mahrukh Naqvi and Qianxing Mo and Ling Zhang and Rikesh Makanji and Yumeng Zhang and Ning Dong and Leidy Isenalumhe and Sameh Gaballa and Julio Chavez and Bijal Shah and Celeste Bello and Lubomir Sokol and Javier Pinilla‐Ibarz},
year = {2026},
journal = {Hematological Oncology},
doi = {10.1002/hon.70235},
url = {https://doi.org/10.1002/hon.70235}
}RIS
TY - JOUR TI - A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T‐Cell Lymphoma AU - Hayder Saeed AU - Melanie Mediavilla Varela AU - Eva Sahakian AU - Mahrukh Naqvi AU - Qianxing Mo AU - Ling Zhang AU - Rikesh Makanji AU - Yumeng Zhang AU - Ning Dong AU - Leidy Isenalumhe AU - Sameh Gaballa AU - Julio Chavez AU - Bijal Shah AU - Celeste Bello AU - Lubomir Sokol AU - Javier Pinilla‐Ibarz PY - 2026 JO - Hematological Oncology DO - 10.1002/hon.70235 UR - https://doi.org/10.1002/hon.70235 ER -
APA
Saeed, H., Varela, M. M., Sahakian, E., Naqvi, M., Mo, Q., Zhang, L., Makanji, R., Zhang, Y., Dong, N., Isenalumhe, L., Gaballa, S., Chavez, J., Shah, B., Bello, C., Sokol, L., & Pinilla‐Ibarz, J. (2026). A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T‐Cell Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70235
Source records
- crossref · retrieved 2026-09-26T19:30:40.864Z